|
Erythropoietic cellular analyses in luspatercept-treated lower-risk myelodysplastic syndromes (MDS): Phase 2 PACE-MDS study. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Celgene; Merck Serono; Novartis; Roche |
Research Funding - Acceleron Pharma |
|
|
|
Research Funding - Acceleron Pharma; Celgene |
|
|
Honoraria - Bristol-Myers Squibb; Celgene; Novartis |
Research Funding - Acceleron Pharma |
|
|
Research Funding - Acceleron Pharma |
Travel, Accommodations, Expenses - Celgene |
|
|
Honoraria - Celgene; Novartis |
Research Funding - Acceleron Pharma; Celgene |
Travel, Accommodations, Expenses - Daiichi Sankyo; Gilead Sciences |
|
|
Research Funding - Acceleron Pharma |
|
|
No Relationships to Disclose |
|
|
Employment - Acceleron Pharma |
Stock and Other Ownership Interests - Acceleron Pharma |
|
|
Employment - Acceleron Pharma |
Stock and Other Ownership Interests - Acceleron Pharma |
|
|
Employment - Acceleron Pharma |
Leadership - Acceleron Pharma |
Stock and Other Ownership Interests - Acceleron Pharma |
|
|
Employment - Acceleron Pharma |
Stock and Other Ownership Interests - Acceleron Pharma |
|
|
Employment - Acceleron Pharma |
Stock and Other Ownership Interests - Acceleron Pharma |
|
|
|
Stock and Other Ownership Interests - Celgene |
|
|
|
Employment - Abbvie; Acceleron Pharma |
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Acceleron Pharma; FibroGen |
|
|
Employment - Acceleron Pharma |
Leadership - Acceleron Pharma; Pulmatrix |
Stock and Other Ownership Interests - Acceleron Pharma; Pulmatrix |
Patents, Royalties, Other Intellectual Property - Acceleron Pharma |
|
|
Research Funding - Acceleron Pharma; Janssen |